Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Pharmacol.

Sec. Neuropharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1618623

This article is part of the Research TopicResearch on Precision Prevention and Treatment of Neurological and Neurodegenerative DiseasesView all 10 articles

Pharmacological Mechanisms and Potential Clinical Applications of Dihydromyricetin in Neurological Disorders

Provisionally accepted
Yike  ZhangYike Zhang1Tingting  ZhangTingting Zhang2Manli  ZhaoManli Zhao2Peichun  LiPeichun Li2Tao  LiuTao Liu2Jiangbo  XieJiangbo Xie2*
  • 1Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China
  • 2Weifang Traditional Chinese Hospital, Weifang, China

The final, formatted version of the article will be published soon.

Neurological disorders (e.g., Alzheimer's disease, Parkinson's disease, and stroke) have complex pathogenesis and affect a substantial proportion of the population; yet, available treatments have poor or limited efficacy, and the patients have a poor prognosis, with high morbidity and mortality. Dihydromyricetin (DHM), a flavonoid compound extracted from plants, has received widespread attention in recent years because of its diverse pharmacological effects. In vitro and in vivo studies have revealed its substantial antioxidant, anti-inflammatory, and neuroprotective properties, making it a promising candidate for the treatment of central nervous system disorders through multiple mechanisms and pleiotropic effects. Therefore, there is an urgent need to develop novel therapeutic strategies. DHM is an attractive candidate for the management of neurological disorders, but there is a lack of a systematic summary of the knowledge status and gaps. Therefore, to address this challenge, we systematically reviewed the pharmacological mechanisms of DHM in central nervous system disorders and its potential applications in related conditions. We analyzed the therapeutic potential and current challenges of DHM to provide a reference for its development and application as a novel therapeutic agent. The review suggests that DHM possesses significant potential for the management of neurological disorders.

Keywords: Dihydromyricetin, Central Nervous System, Pharmacological effects, Alzheimer's disease, Parkinson's disease

Received: 26 Apr 2025; Accepted: 29 Jun 2025.

Copyright: © 2025 Zhang, Zhang, Zhao, Li, Liu and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jiangbo Xie, Weifang Traditional Chinese Hospital, Weifang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.